Researchers led by Stephan, Cummings, and Fitzgerald reported a novel orally administered foam that delivers gene therapy locally to constrictive esophageal carcinoma, enabling targeted transduction of affected tissue while minimizing systemic exposure. The approach addresses delivery barriers for cancers in anatomically difficult sites. Preclinical data show localized uptake and therapeutic gene expression with reduced off-target biodistribution compared with systemic vectors. The formulation leverages foam rheology to adhere to mucosal surfaces, increasing residence time for transduction. Translating to human trials will require demonstration of manufacturing scalability, vector safety in mucosal delivery, and durable therapeutic effect. If successful, this delivery modality could open oral or topical gene therapy avenues for other luminal cancers and mucosal diseases.